Companies around the world are confronting new risks of corporate misconduct in the rush to respond to the coronavirus outbreak, a global pandemic that has presented pitfalls as cost-cutting and other priorities threaten to undercut compliance programs.
In the scramble to address the global health crisis, governments and companies have been coordinating on the approval and distribution of potential treatments, medical equipment and other necessary products, leaving fertile ground for corruption in the space between the public and private sectors.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]